Your browser is no longer supported. Please, upgrade your browser.
Settings
MRK Merck & Co., Inc. daily Stock Chart
MRK [NYSE]
Merck & Co., Inc.
IndexDJIA S&P500 P/E59.38 EPS (ttm)1.03 Insider Own0.04% Shs Outstand2.72B Perf Week6.39%
Market Cap166.72B Forward P/E14.97 EPS next Y4.09 Insider Trans-13.33% Shs Float2.72B Perf Month9.00%
Income2.85B PEG12.36 EPS next Q0.94 Inst Own76.00% Short Float0.80% Perf Quarter-3.51%
Sales39.80B P/S4.19 EPS this Y-10.00% Inst Trans-0.33% Short Ratio1.62 Perf Half Y-2.64%
Book/sh14.03 P/B4.37 EPS next Y3.80% ROA3.00% Target Price66.86 Perf Year1.57%
Cash/sh4.11 P/C14.89 EPS next 5Y4.80% ROE7.20% 52W Range53.63 - 66.80 Perf YTD8.90%
Dividend1.92 P/FCF- EPS past 5Y-7.00% ROI6.40% 52W High-8.33% Beta0.80
Dividend %3.13% Quick Ratio1.20 Sales past 5Y-3.70% Gross Margin68.60% 52W Low14.18% ATR1.03
Employees68000 Current Ratio1.40 Sales Q/Q-2.00% Oper. Margin8.30% RSI (14)75.04 Volatility2.14% 1.35%
OptionableYes Debt/Eq0.71 EPS Q/Q-102.60% Profit Margin7.20% Rel Volume0.57 Prev Close61.28
ShortableYes LT Debt/Eq0.57 EarningsFeb 02 BMO Payout179.70% Avg Volume13.40M Price61.24
Recom2.10 SMA206.08% SMA508.63% SMA200-0.55% Volume4,474,460 Change-0.07%
Jan-16-18Upgrade SunTrust Hold → Buy
Nov-28-17Resumed BofA/Merrill Buy $64
Nov-24-17Reiterated Deutsche Bank Hold $62 → $59
Oct-31-17Upgrade Jefferies Underperform → Hold
Oct-30-17Downgrade SunTrust Buy → Hold
Oct-30-17Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-30-17Downgrade Barclays Overweight → Equal Weight $72 → $62
Oct-18-17Upgrade Citigroup Neutral → Buy
Aug-09-17Upgrade HSBC Securities Reduce → Hold
Jul-31-17Reiterated UBS Buy $70 → $72
Jan-13-17Initiated Bryan Garnier Buy
Jan-12-17Upgrade Piper Jaffray Neutral → Overweight
Jan-12-17Upgrade Morgan Stanley Equal-Weight → Overweight
Jan-12-17Upgrade Guggenheim Neutral → Buy
Dec-19-16Downgrade Jefferies Hold → Underperform
Oct-13-16Upgrade BofA/Merrill Neutral → Buy
Sep-09-16Reiterated Barclays Overweight $66 → $72
Aug-08-16Upgrade Credit Suisse Neutral → Outperform $73
Aug-08-16Reiterated Deutsche Bank Hold $58 → $59
Apr-06-16Initiated Societe Generale Buy $80
Jan-22-18 12:20PM  Will These 4 Large-Cap Drug Stocks Be Big Winners This Earnings Season? InvestorPlace
10:32AM  Analyst Ratings and Recommendations for Johnson & Johnson Market Realist
10:31AM  Analysts Future Estimates for Merck & Co. Market Realist
10:22AM  Bristol-Myers (BMY) Reports Data from CheckMate-142 Study Zacks
10:00AM  Behind Novartiss 4Q17 Earnings: Why Some Expect Revenue Growth Market Realist
09:42AM  AstraZeneca's PARP Inhibitor Lynparza Gets Approval in Japan Zacks
09:02AM  Johnson & Johnsons Medical Devices Segment: 4Q17 Estimates Market Realist
09:01AM  Merck & Co.s Animal Health Business in 3Q17 Market Realist
07:32AM  Merck & Co.s Cardiovascular and Immunology Products in 3Q17 Market Realist
07:31AM  What Analysts Recommend for Bristol-Myers Squibb in January 2018 Market Realist
Jan-21-18 12:25PM  Merck leaps past rivals with latest lung cancer drug results MarketWatch
Jan-19-18 11:33AM  Merck & Co., Inc.s Rally Could Burn Investors InvestorPlace
10:34AM  Merck & Co.s Diabetes Products in 3Q17 Market Realist
10:32AM  Opdivo Could Be Long-Term Growth Driver for Bristol-Myers Squibb Market Realist
09:35AM  Johnson & Johnsons Revenue Estimates for 4Q17 Market Realist
09:05AM  Merck & Co.s Human Vaccines Business in 3Q17 Market Realist
09:03AM  What to Expect from Bristol-Myers Squibbs Yervoy in 2018 Market Realist
08:54AM  These Two Biotechs Just Reported Key Data Market Exclusive
08:05AM  Johnson & Johnsons 4Q17 Earnings on January 23: What to Expect Market Realist
07:34AM  Keytruda: Merck & Co.s Immuno-Oncology Blockbuster Drug Market Realist
06:45AM  First-Time Data for Mercks KEYTRUDA® (pembrolizumab) in Patients with Previously Treated Advanced Hepatocellular Carcinoma (HCC) to be Presented at 2018 ASCO GI Symposium Business Wire
06:30AM  LYNPARZA® (olaparib) Receives Approval in Japan for the Treatment of Advanced Ovarian Cancer Business Wire
05:55AM  Pharma Stock Roundup: Merck's Keytruda Shines in Study, Priority Review for Kymriah Label Expansion Zacks
Jan-18-18 05:30PM  Merck & Co.s Business Segments and Performance in 3Q17 Market Realist
04:00PM  Merck & Co.s Quarterly Revenue Trend Market Realist
02:28PM  Mercks & Co.s Valuation in January 2018 Market Realist
01:55PM  3 Biotech Stocks Start Healthy in 18: Will the Rally Last? InvestorPlace
11:24AM  Merck & Co., Inc. Stock Could Still Soar Another 10% From Here InvestorPlace
10:00AM  Opdivo Could Be Key Revenue Driver for Bristol-Myers Squibb in 2018 Market Realist
04:00AM  The Consumer Health of Merck Walks the Talk with its WE100 Movement CNW Group
Jan-17-18 10:48AM  Merck Strong on Confirmatory Phase III Lung Cancer Study Zacks
09:36AM  Ignore the Gaps and Merck Is Ready for Further Strong Gains TheStreet.com
09:03AM  Merck & Company: S&P 500s Top Gainer on January 16 Market Realist
08:53AM  Merck (MRK) Jumps: Stock Rises 5.8% Zacks
08:00AM  Todays Research Reports on Stocks to Watch: Bristol-Myers Squibb Company and Merck & Co. ACCESSWIRE
Jan-16-18 05:17PM  What Happened in the Stock Market Today Motley Fool +5.81%
04:17PM  Indexes Reverse Lower In Volatile Session; Bitcoin Slumps, Breakouts Fade Investor's Business Daily
04:11PM  Dow Finishes Lower After Surpassing 26,000; S&P 500 and Nasdaq Also Decline TheStreet.com
02:08PM  Merck & Co., Inc. (MRK) Stock Surges on Lung Cancer Drug Success InvestorPlace
01:56PM  Merck Soars as Lung Cancer Study Meets Goals TheStreet.com
01:19PM  Early Keytruda Results Win Merck An Upgrade Benzinga
12:01PM  Positive Keytruda lung cancer data sends Merck shares up 6 pct Reuters
11:00AM  UPDATE: Merck shares jump 7% on news of positive results from lung cancer trial MarketWatch
10:30AM  Whats Teva Pharmaceuticals Research and Development Strategy? Market Realist
09:28AM  Stocks to Watch: Citigroup, GE, UnitedHealth, Apple, Alphabet, Amazon, Ford, Fiat Chrysler, GM, Merck The Wall Street Journal
09:12AM  Dow Futures Set For Broad Rally; Drug Giant Spikes, Bitcoin Tumbles Investor's Business Daily
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
06:59AM  Merck's Keytruda succeeds in key lung cancer trial Reuters
06:45AM  Merck's KEYTRUDA(R) (pembrolizumab) Significantly Improved Overall Survival and Progression-Free Survival as First-Line Treatment in Combination with Pemetrexed and Platinum Chemotherapy for Patients with Metastatic Nonsquamous Non-Small Cell Lung Cancer (KEYNOTE-189) Business Wire
Jan-15-18 10:22AM  AstraZeneca's Lynparza Label Now Includes Breast Cancer Zacks
09:05AM  What Are Insys Therapeutics Top Priorities? Market Realist
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
Jan-12-18 05:20PM  Whats behind Insys Therapeutics Legal Tangles? Market Realist
03:50PM  A Look at Insys Therapeutics Financial Performance Market Realist
02:17PM  What Analysts Recommend for Insys Therapeutics and Peers Market Realist
12:45PM  U.S. FDA Approves LYNPARZA® (olaparib) in Germline BRCA-Mutated Metastatic Breast Cancer Business Wire
09:10AM  Dow 30 Stock Roundup: Boeing Q4 Deliveries Up Y/Y, Success for Merck's Keytruda Combo Zacks
09:01AM  What Analysts Recommend for Roche in January 2018 Market Realist
08:37AM  Merck's Keytruda on a Roll: Can it Retain the Spark in 2018? Zacks
07:32AM  Zelboraf Could Boost Roches Sales Growth in 2018 Market Realist
07:31AM  Wall Street Recommendations for Mylan in January 2018 Market Realist
Jan-11-18 02:55PM  Here's whats next for OpGen as it faces delisting threat American City Business Journals
10:33AM  Developments for Ionis Pharmaceuticals Post-3Q17 Market Realist
10:32AM  Recent Developments for Mylan Market Realist
09:45AM  Major Pharma Short Interest Takes a Plunge 24/7 Wall St.
09:04AM  TEVA Stock Price Rises on Generic Launch of Viread Market Realist
09:03AM  What to Expect from Roches Tecentriq and Avastin in 2018 Market Realist
09:02AM  How Mylans Rest of the World Segment Performed in 3Q17 Market Realist
08:01AM  See what the IHS Markit Score report has to say about Merck & Co Inc. Markit
07:34AM  Tevas Launch of Generic Version of Reyataz Boosts Stock Market Realist
05:29AM  Valeant Pharmaceuticals Intl Inc Stock Is Worth the Risk InvestorPlace
Jan-10-18 12:06PM  Why Nestle Is Eyeing Merck's Consumer Health Unit Bloomberg Video
10:33AM  AbbVies Rova-T: Can Label Expansion Make It a Blockbuster Drug? Market Realist
09:05AM  AbbVies Rova-T and the Treatment of Small Cell Lung Cancer Market Realist
08:55AM  Merck's Keytruda Combo Gets Breakthrough Therapy Status Zacks
07:38AM  AbbVies Rova-T: Solid Growth Driver for the Future? Market Realist
07:37AM  Mylans Renaissance and Agila Acquisitions Market Realist
07:31AM  AbbVies Position in the Growing Oncology Market in 2018 Market Realist
Jan-09-18 05:15PM  AbbVie Rapidly Advancing Its 2018 Solid Tumor Portfolio Market Realist
03:57PM  U.S. pharma executives expect deals to pick up after tax overhaul Reuters
03:35PM  What Mylan Expects for Fiscal 2017 Market Realist
02:05PM  Exploring Mylans Diversified Portfolio of Brands Market Realist
01:25PM  Assessing Incytes 3Q17 Product Portfolio Market Realist
12:32PM  Analysts Recommendations for Mylan Market Realist
12:18PM  After Irrational Fire Sale, Its Time to Buy the Dip in Merck & Co., Inc. Stock InvestorPlace
10:42AM  Amgen Announces Acceptance of MAA for Evenity in Europe Zacks
10:38AM  Merck's (MRK) Keytruda Succeeds in High-Risk Melanoma Study Zacks
10:23AM  Examining Incytes Quarterly Revenue Trend Market Realist
06:45AM  Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy for Advanced and/or Metastatic Renal Cell Carcinoma PR Newswire
12:57AM  Despite Setbacks, Drugmakers Have Plans to Fight Alzheimers The Wall Street Journal
Jan-08-18 07:54PM  Drug Industry Isn't Giving Up on Alzheimer's The Wall Street Journal
06:16PM  Merck CEO says more of drug rebates should end up with consumers CNBC
04:21PM  Merck CEO: We continue to work with Trump Administration ... CNBC Videos
11:52AM  Celgene deal could be the first of many for biopharma as new tax law frees up cash CNBC
06:45AM  Mercks KEYTRUDA® (pembrolizumab) Significantly Improved Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy in Patients with Stage 3 Resected High-Risk Melanoma (EORTC1325/KEYNOTE-054) Business Wire
06:30AM  FDA Accepts New Drug Applications for Mercks Doravirine, the Companys Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI), for Treatment of HIV-1 Infection Business Wire
02:26AM  [$$] Safety Fears Threaten Global Dengue Vaccine Effort The Wall Street Journal
12:13AM  [$$] Safety Fears Threaten Global Dengue Vaccine Effort The Wall Street Journal
Jan-05-18 09:48AM  Cancer Space Update: New Regulatory Status for 3 Major Drugs Zacks
08:31AM  The Slow Push Upward Continues for Johnson & Johnson Stock InvestorPlace
Merck & Co., Inc. provides healthcare solutions worldwide. It operates in four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic agents to treat cardiovascular, type 2 diabetes, asthma, nasal allergy symptoms, allergic rhinitis, chronic hepatitis C virus, HIV-1 infection, fungal and intra-abdominal infections, hypertension, arthritis and pain, inflammatory, osteoporosis, and fertility diseases. It also provides neuromuscular blocking agents; anti-bacterial products; cholesterol modifying medicines; and vaginal contraceptive products. In addition, the company offers products to prevent chemotherapy-induced and post-operative nausea and vomiting; treat brain tumors, and melanoma and metastatic non-small-cell lung cancer; prevent diseases caused by human papillomavirus; and vaccines for measles, mumps, rubella, varicella, chickenpox, shingles, rotavirus gastroenteritis, and pneumococcal diseases. Further, it offers antibiotic and anti-inflammatory drugs to treat infectious and respiratory diseases, fertility disorders, and pneumonia in cattle, horses, and swine; vaccines for poultry; parasiticide for sea lice in salmon; and antibiotics and vaccines for fishes. The company also provides companion animal products, such as ointments; diabetes mellitus treatment for dogs and cats; anthelmintic products; fluralaner products to treat fleas and ticks in dogs; and products for protection against bites from fleas, ticks, mosquitoes, and sandflies. It has collaborations with Aduro Biotech, Inc.; Premier Inc.; Cancer Research Technology; Corning; Pfizer Inc.; AstraZeneca PLC.; SELLAS Life Sciences Group Ltd.; and Aeglea BioTherapeutics, Inc. It serves drug wholesalers and retailers, hospitals, government agencies and entities, physicians, physician distributors, veterinarians, distributors, animal producers, and managed health care providers. The company was founded in 1891 and is headquartered in Kenilworth, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Option Exercise44.3052,0002,303,600153,484Jan 16 05:12 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Option Exercise36.5650,9941,864,34150,994Jan 16 05:13 PM
Holston Michael JEVP, General CounselJan 16Sale61.6312,500770,37549,092Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,6083,118,97162,766Jan 16 05:13 PM
Schechter Adam HEVP & Pres-Global Human HealthJan 16Sale61.6350,9943,142,7600Jan 16 05:13 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 16Sale61.6360,0003,697,80093,484Jan 16 05:12 PM
GRADDICK WEIR MIRIAN MExe V-P, HRJan 12Sale58.005,000290,000101,484Jan 16 05:12 PM
GLOCER THOMAS HDirectorNov 08Option Exercise38.045,000190,20010,100Nov 09 03:52 PM
GLOCER THOMAS HDirectorNov 08Sale56.205,000280,9835,100Nov 09 03:52 PM
KIDDER C ROBERTDirectorMay 12Option Exercise35.195,000175,95014,317May 12 04:58 PM
KIDDER C ROBERTDirectorMay 12Sale63.545,000317,6959,317May 12 04:58 PM
Davis Robert MEVP, Global Svcs & CFOMay 09Option Exercise0.0085,8810118,031May 09 04:42 PM
AMBROSE ADELE DSr.V-P & Chief Comuns OfficerMay 09Option Exercise0.002,576023,668May 09 04:42 PM
Karachun Rita ASr. VP Fince-Global ControllerMay 09Option Exercise0.002,576017,068May 09 04:42 PM
Chattopadhyay SanatExe V-P & Pres. MMDMay 02Option Exercise0.003,092043,637May 03 09:54 AM
Gerberding Julie L.EVP Strat Comm, Gl Pub PolicyMay 02Option Exercise0.003,092046,416May 03 09:52 AM
Schechter Adam HEVP & Pres-Global Human HealthApr 03Sale63.4853,8503,418,166116,336Apr 04 06:36 PM
Karachun Rita ASr. VP Fince-Global ControllerFeb 14Sale64.732,954191,22711,675Feb 15 11:30 AM
RUSSO PATRICIA FDirectorFeb 08Option Exercise35.195,000175,95018,148Feb 09 12:52 PM
RUSSO PATRICIA FDirectorFeb 08Sale64.425,000322,12113,148Feb 09 12:52 PM
WEEKS WENDELL PDirectorFeb 06Option Exercise51.865,000259,3005,100Feb 06 03:35 PM
WEEKS WENDELL PDirectorFeb 06Sale64.515,000322,542100Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Option Exercise32.5115,000487,65016,000Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Option Exercise59.0977,9594,606,471142,239Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Option Exercise34.3536,3351,248,17336,335Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Option Exercise35.195,000175,9505,100Feb 06 03:35 PM
Cech Thomas RDirectorFeb 03Sale63.425,000317,100100Feb 06 03:35 PM
Schechter Adam HEVP & Pres-Global Human HealthFeb 03Sale63.7336,3352,315,6990Feb 06 03:35 PM
Holston Michael JEVP, General CounselFeb 03Sale63.9691,9595,881,25250,280Feb 06 03:35 PM
WENDELL PETER CDirectorFeb 03Sale63.6915,000955,4061,000Feb 06 03:35 PM